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Summary Kawasaki disease (KD) is an important and common inflammatory vas-
culitis of early childhood with a striking predilection for the coronary arteries. It is the
predominant cause of paediatric acquired heart disease in developed countries.
Despite 40 years of research, the aetiology of KD remains unknown and consequently
there is no diagnostic test and treatment is non-specific and sub-optimal. The
consensus is that KD is due to one or more widely distributed infectious agent(s),
which evoke an abnormal immunological response in genetically susceptible indivi-
duals. The epidemiology of KD has been extensively investigated in many populations
and provides much of the supporting evidence for the consensus regarding etiology.
These epidemiological data are reviewed here, in the context of the etiopathogen-
esis. It is suggested that these data provide additional clues regarding the cause of KD
and may account for some of the continuing controversies in the field.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.What is Kawasaki disease?
Kawasaki disease (KD) is an acute systemic necrotis-
ing panvasculitis affecting medium-sized arteries,
particularly thecoronaryarteries.1 It is characterised
by prolonged fever (of at least five days duration) and
a collection of clinical features (rash, non-purulent
conjunctivitis, oropharyngeal changes, lymphadeno-* Corresponding author. Tel.: +61 8 9340 7061;
fax: +61 8 9388 2097.
E-mail address: dburgner@paed.uwa.edu.au (D. Burgner).
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doi:10.1016/j.ijid.2005.03.002pathy and changes to the extremities) that together
comprise the standard diagnostic criteria (Table 1).2
As the clinical phenotype is essentially a constella-
tion of clinical signs of unknown etiology (vide infra),
it may be more appropriate to refer to ‘Kawasaki
syndrome’ rather than ‘Kawasaki disease’.3 Other
clinical features, such as extreme irritability and
re-inflammation of a recent BCG scar may aid the
diagnosis.4,5 The full diagnostic criteria — fever 5
days, plus at least four clinical criteria — were ori-
ginally derived for epidemiological studies in Japan.3
The clinical features often appear sequentially, ines. Published by Elsevier Ltd. All rights reserved.
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Table 1 Diagnostic criteria for Kawasaki disease (for
a detailed discussion of the clinical diagnosis and
additional clinical features, see references5,6,97).
Fever of at least five days duration plus at least four
of the following features:
Polymorphous rash
Bilateral non-purulent conjunctivitis
Changes in the peripheries
Oropharyngeal changes
Cervical lymphadenopathyno predefined order and some may even be absent
on presentation. In many children the clinical pre-
sentation is striking and KD patients are often mis-
diagnosed with severe sepsis. However, KD can have
similar clinical features to other common childhood
illnesses, such as measles, rubella and scarlet fever.
These children may present a diagnostic challenge6
and the lack of a specific diagnostic test may delay
treatment and thus worsen prognosis.7
Moreover, to confuse the clinical picture further,
there is increasing concern that the diagnostic
criteria are too narrow. ‘Atypical’ or ‘incomplete’
KD is a description used for children presenting
with the characteristic fever but fewer than four
classical signs. A better descriptive term is ‘incom-
plete KD’ because these children do not demon-
strate atypical signs, just fewer of them. Cervical
lymphadenopathy is the least commonly observed
of the diagnostic criteria, occurring in about three
quarters of usually older children, whilst prolonged
fever and peripheral desquamation have been
reported as the commonest diagnostic features.
Incomplete KD may be poorly recognised and
occurs more often in infants.8 Children presenting
with incomplete KD are at higher risk of developing
coronary artery lesions both because of their young
age and their potential for not receiving timely
immunoglobulin treatment.8 Interestingly, as many
as 10% of the children reported in the original
report of the syndrome2 would not fulfil the cur-
rent case definition.3 The clinical diagnostic cri-
teria need refinement to increase their positive
predictive value and recent guidelines have been
developed in an attempt to increase the sensitivity
of the clinical diagnosis.5 It is unclear how these
will perform in clinical practice. Although these
guidelines are intended only as a clinical tool, they
are likely to have an impact on the reported
epidemiology of KD.
Cardiovascular sequelae
Kawasaki disease is clearly not the benign childhood
exanthem initially proposed1,2 and has significantlong-term implications. Kawasaki disease is the
most common cause of paediatric acquired heart
disease in the world.3 Coronary artery lesions (pre-
dominantly aneurysms) occur in up to 30% of
untreated and 5—10% of treated children;1,9,10 the
poor outcome despite adequate treatment reflects
an incomplete understanding of the etiopathogen-
esis. Acute mortality in KD is increased significantly,
with deaths predominantly occurring from myocar-
dial infarction following occlusion of giant coronary
aneurysms.11,12 Overall, myocardial infarction
occurs in 2% of those with coronary artery
lesions.13 Lifelong medical therapy, coronary artery
grafting and even heart transplantation may be
required.1 Crucially, in children without coronary
artery lesions who die of other causes, the coronary
arteries are almost invariably markedly abnormal,
with striking pro-atherosclerotic changes.14,15
Abnormal in vivo function in non-coronary arteries16
suggests that cardiovascular damage post-KD is both
pervasive and persistent, even in the absence of
acute coronary artery lesions. Thus, there is intense
speculation that KD is pro-atherosclerotic, but defi-
nitive long-term data are lacking.
Regressed coronary artery lesions result in abnor-
mal coronary artery function17 and histological
changes that are pro-atherosclerotic.15,18 The simila-
rities between KD and adult cardiovascular pathology
suggest that KD may be a useful paradigm for inves-
tigating the etiopathogenesis of atherosclerosis.19Does Kawasaki disease represent an
extreme phenotype of a more
pervasive phenomenon?
It is possible that KD is not a distinct entity, but the
more clinically obvious end of a spectrum of patho-
genic processes. KD may therefore reflect an
extreme clinical phenotype where childhood infec-
tions predispose to subsequent endothelial damage
and cardiovascular pathology. Thus in genetically
susceptible children, acute infections such as those
causing fever and rash, may result in unrecognised
damage to the cardiovascular system that later
manifests itself as adult cardiovascular disease.
Adult atherosclerotic disease (like KD) has not been
reliably associated with a single infectious etiology,
but correlates with overall infectious burden.20
Furthermore, acute childhood infections are accom-
panied by pro-atherosclerotic phenomena and sub-
sequent thickening of the arterial intima.21
Understanding the etiopathogenesis of KD may
therefore identify common gene—environment
interactions that are involved in adult cardiovascu-
lar disease.
Kawasaki disease: What is the epidemiology telling us about the etiology? 187Why is it important to understand the
etiology and pathogenesis of Kawasaki
disease?
The timely diagnosis of KD is essential in maximising
the prevention of overt coronary damage; treat-
ment beyond ten days of onset is associated with
a worse outcome and an increased incidence of
coronary abnormalities.22,23 The lack of a specific
diagnostic test and the limited clinical utility of the
current clinical diagnostic criteria mean that the
diagnosis is often delayed, even in populations
where the condition is well recognised.24 The cur-
rently accepted best treatment (intravenous immu-
noglobulin and aspirin (Table 2)6 fails to prevent
coronary artery abnormalities (identifiable by ima-
ging) in up to 10% of cases.25 Specific diagnostic
test(s) and rational interventions could be readily
developed if the etiopathogenesis of KD was fully
understood. Moreover, preventative treatments
such as vaccines would be justified in populations
with the highest KD incidence, where KD affects 1—
2% of all children, such as Korea and Japan.3
The consensus view is that KD results from a
widely distributed infectious agent (or possibly
agents) that causes the clinical syndrome in
genetically susceptible children. Much of the sup-
porting data for this viewpoint is provided by
epidemiological studies in a variety of populations.
KD is described in all ethnic groups, but the inci-
dence varies dramatically (see below). The homo-
geneity of the clinical phenotype and epidemiology
suggest that KD arises from common disease pro-
cesses, although the antigenic trigger(s) and/orTable 2 Treatment of Kawasaki disease (for detailed disc
ences5,6,97).
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populations.Epidemiological evidence for an
infectious cause
Kawasaki disease shows a striking age distribution
reminiscent of other childhood infections. Over 80%
of cases occur between the ages of six months and
four years,26 although the condition occurs rarely
both earlier27 and later28 in life. The low incidence
of KD in both the first six months suggests that most
infants are protected by passively acquired mater-
nal antibody against the causative agent(s). A tran-
sient immunological immaturity may also account
for the low incidence in the first few months post-
natally.29 The low incidence of KD beyondmid-child-
hood suggest a ubiquitous antigen(s) that most
children encounter uneventfully in early childhood
and to which they mount an appropriate and pro-
tective immune response. Kawasaki disease is more
common in boys (male:female ratio 1.6:1)1 a fea-
ture observed in many infectious diseases30,31 and
also in coronary atherosclerosis, where sex differ-
ences in immune responses are suggested to med-
iate susceptibility.32
Seasonal variation in KD incidence is well recog-
nised, but the predominant season varies in differ-
ent countries. In the UK,33 Australia24 and the
USA34,35 KD is most common in winter and spring.
In China, spring and summer predominate36 and in
Korea KD incidence is highest in summer months.37
In Japan, which reports the highest KD incidence,ussion of the treatment of Kawasaki disease see refer-
of 2 g/kg given as a single infusion over 10—12 hours
rdiac status necessitates infusing the dose more
in divided doses). Failure to respond to this initial IVIG
ually treated with a second dose (usually 2 g/kg as a
usion). Failure to respond to the second IVIG dose is
ated with intravenous methylprednisolone under
pervision
of aspirin is controversial and its utility has never
en in a randomised controlled trial. It remains,
part of the standard management of KD. Generally
e’ aspirin (50—100 mg/kg/day in divided doses) is
tely until the fever defervesces, when ‘low dose’
—5 mg/kg/day) is given until an echocardiogram
eks after the KD diagnosis is normal. If the six week
iogram is abnormal, aspirin is usually continued under
ical supervision
kine therapies and other interventions are generally
but have occasionally been used. For a review
urger and Fullton5
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explanation for these divergent data is that season is
a marker for weather conditions that have a more
direct role in determining the incidence. In the US,
KD incidence clearly correlates negatively with
average ambient temperature and positively with
average rainfall in the preceding month.39 Studies
are underway investigating similar parameters in
the UK.
It is unknown whether the meteorological condi-
tions themselves predispose to KD, or, more plau-
sibly, if they alter the epidemiology of etiological
agents. The lack of consistent seasonal associations
in different countries raises the possibility that
various etiological agents may be involved in the
etiology of KD. Geographical clustering of KD cases
and epidemics have been reported from a number of
countries,40—44 although they have been much less
frequently reported in the past decade, possibly
suggesting a changing epidemiology. In Japan, which
has provided the most comprehensive epidemiolo-
gical data, epidemics of KD have been described
with a clear epicentre and documented geographi-
cal spread across the whole nation within six
months.42
These epidemiological data clearly indicate an
infectious etiology for KD. The clinical features of
the disease are also characteristic of a severe acute
childhood infection. It seems likely that the causa-
tive agents are widely distributed and are also highly
immunogenic, at least in most children, as moreTable 3 Proposed but unproven causes of Kawasaki
disease.
Putative etiological agent/
environmental association
References
Adenovirus 98
Herpesvirus 99
Mycoplasma species 100
Toxigenic streptococci 101,102
Viridans streptococci 103
Toxigenic staphylococci 104,105
Propionibacterium acnes 106,107
Ehrlichia chaffeensis 108,109
Rickettsia species 110,111
Epstein Barr virus 112—114
Retrovirus 115—117
Human coronavirus New Haven 48
Measles virus 118,119
Chlamydia pneumoniae 120—122
Bartonella henselae 109
Coxiella burnetii 123,124
House dust mite 125
Mercury 126
Carpet shampoo 127,128
Residence near body of water 129than one episode of KD is rare. Recurrent KD is
reported in 1—3% of children,45 although it appears
less common in Caucasians.46 It may reflect a spe-
cific immunological deficiency in these children or
exposure tomore than one causative agent.3 Various
environmental causes of KD have been repeatedly
suggested (Table 3), but none has been consistently
replicated. However, the possibility of environmen-
tal factors influencing etiology, possibly by modulat-
ing infection risk, remains a possibility.Which infection?
The search for a single unifying microbiological
cause has been unrelenting but, to date, fruitless.
Standard microbiological techniques, molecular
methods and serological investigations have so far
failed to identify an etiological agent. Molecular
techniques fail to detect circulating conserved
microbial sequences in KD,47 indicating that the
antigenic stimulus may arise from a distant site
(e.g. colonising pathogens in the nasopharynx)
and/or may represent host-derived factor(s) that
induce or promote the pro-inflammatory cascade.
The list of discarded and/or unproven etiological
agents in KD is long (Table 3). A recent report of an
association between the presence of genetic mate-
rial from a novel coronavirus and Kawasaki disease
in a handful of cases48 remains unproven and may
reflect an epiphenomenon; the putative etiological
agent is a relatively common viral pathogen in young
children and it is unclear how long the DNA persists.
The lack of a unifying etiological agent despite a
significant research effort suggests that KD can
follow exposure to more than one infectious agent,
or that a novel infectious agent is involved. Alter-
natively the clinical phenotype may reflect a stereo-
typed response in a genetically-susceptible host to
one of a variety of infectious agents.
Much of the continuing debate in the literature
concerns whether KD is caused by a superantigen49
or a conventional antigen.50 KD shares many clinical
features with superantigen-mediated diseases (for
example, rash, conjunctivitis and skin peeling) and
KD has occasionally been reported concurrently in
children with toxic—shock syndrome, which is
caused by superantigens.51 However, unequivocal
epidemiological and laboratory support for a role
for superantigens in KD is lacking. In one small study,
maternal antibodies against toxic shock syndrome
toxin-1 appeared protective against early-onset
KD.52 However, the carriage rates of superanti-
gen-producing bacteria by children with KD are
not consistently increased,53,54 although these data
may reflect the involvement of as yet unidentified
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capable of causing KD. Superantigens bind to the
Vb region of the T-cell receptor and clonal expansion
of Vb2-expressing T-cells has been reported in some
studies of KD,55 but again the finding is inconsis-
tent.56 Other studies have reported oligoclonal IgA-
producing plasma cells infiltrating bronchial and
intestinal tissues in fatal KD,57 which suggests the
involvement of a conventional antigen.How many infections?
Much of the controversy and inconsistency surround-
ing the nature of the infectious trigger in KD might
reflect multiple etiological agents resulting in the
same clinical phenotype. It is possible, for example,
that a viral upper respiratory tract infection may
alter local immunity and allow elaboration of super-
antigens by colonising bacteria in the nasopharynx.
Certainly the epidemiology of KD, with rapid
changes in incidence, seasonal variation and the
relationship between incidence and weather condi-
tions is more redolent of acute viral infections58,59
than bacterial colonisation, which alters more
slowly.60 In meningococcal disease, influenza infec-
tion acts in an analogous way, and meningococcal
epidemics often follow influenza outbreaks.61,62
This hypothesis could be addressed through large
detailed prospective epidemiological studies.
Another possibility is that either pathogen or host
factors modulate the behaviour of an antigen, so
that it behaves both as a conventional antigen
and as a superantigen. Heat shock proteins are
increased in acute inflammatory conditions, includ-
ing KD63 and cross-reactivity with certain heat
shock proteins is thought to be responsible for the
inflammation of the BCG scar in KD.64 Heat shock
proteins have been reported to alter the behaviour
of superantigens, so that the immune system recog-
nises them as conventional antigens65 and also can
greatly up-regulate pro-inflammatory responses to
conventional antigens.66 The possibility of endogen-
ous stimuli that profoundly suppress or enhance
antigenic effects has not previously been consider-
ed in KD, but might account for much of the
controversy surrounding the roles of conventional
or superantigens.Epidemiological evidence for genetic
determinants of Kawasaki disease
susceptibility and outcome
Whatever the etiological trigger(s) for KD, there is
clear evidence that host genetic determinants playa major role in both susceptibility and probably
outcome in KD. Genetic studies of KD are therefore
likely to be highly informative about etiology and
pathogenesis. Although KD is reported in all ethnic
groups, the variation in incidence of KD between
(and to a lesser extent within) countries is striking.
The annual incidence varies from approximately
three (per 100,000 children <5 years of age) in
South America, to four in Australia,24 eight in the
UK,33 4—15 in the US,1 20—30 in China36 and Hong
Kong67 50 in Taiwan,68 90 in Korea37 and >130 in
Japan69 The reported incidence is probably under-
estimated in many countries as atypical cases are
not included. Australian data (Burgner et al., unpub-
lished) suggest an incidence 50% higher than that
recorded through active surveillance.24 In a number
of countries the incidence of KD appears to be
increasing.33,68,69 Whilst this may be partly attribu-
table to increased awareness, the increasing inci-
dence is reported in countries where the disease has
been widely recognised for several years and where
a standard case definition is employed and may
therefore reflect changing epidemiology.
The incidence of KD is therefore greatest in
north-east Asians, especially in Koreans and Japa-
nese. It is estimated that 1—2% of all hospitalised
Korean children have KD (Park YW, personal com-
munication) and that KD affects one in 150 Japanese
children.3 This indicates genetic factors may be
central in determining susceptibility, especially as
the incidence rate remains high in those migrating
to lower incidence countries. For example, the
incidence of KD in Japanese Americans in Hawaii
(135/100,000 <5 years) is identical to the highest
rates reported from Japanese living in Japan.67
The incidence rate in siblings of affected children
is 10—15 fold higher than the population incidence in
Japan.70 The ratio of sibling to population incidence
is termed the ‘heritability’ or ‘ls’. Sibling rates out-
side Japan are unknown, but reports fromCaucasians
support this trend71 and sibling rates in Korea37
(Burgner, unpublished observations) also support this
high heritability. This figure is slightly less than the
heritability for insulin-dependent diabetes (ls  15)
and 4 times higher than that of asthma,72 suggest-
ing a striking genetic predisposition to develop the
disease in a minority of children across different
ethnic groups. In addition, the incidence of previous
KD in parents of Japanese children with KD is sig-
nificantly increased and these families are much
more likely to have other affected children and child-
ren with recurrent disease.73 Taken together, these
epidemiological dataprovideconvincingevidence for
a major role for host genetics in KD susceptibility.
Whilst there are concerns that cardiovascular
damage may be pervasive in KD, overt coronary
190 D. Burgner, A. Harndenartery lesions only develop in a minority of children.
In acute KD all arms of the innate and adaptive
immune response are activated, but lymphocytes,
macrophages and neutrophils are central.74 The
extent and kinetics of host inflammation strongly
correlates with the risk of coronary damage. The
duration of fever prior to treatment,75—77 the max-
imal erythrocyte sedimentation rate,78 the extent
of pro-inflammatory cytokine production79,80 and
the degree of neutrophil activation81 have all been
shown to be risk factors for coronary damage. The
extent of the host inflammatory response is partly
genetically determined.82 Genetic factors are
therefore likely to be important in determining
outcome in KD and genetic studies may identify
key pathogenic mediators and ultimately guide
the development of new interventions.Genetic epidemiological studies of KD
Kawasaki disease is likely to be a genetically ‘com-
plex disease’, with contributions from a number of
genetic loci to susceptibility and outcome. Associa-
tions between genetic variants at candidate loci and
KD susceptibility and outcome may be extremely
informative about the role of specific mediators in
etiopathogenesis, allowing investigation of hypoth-
eses suggested by the clinical data, but untestable
by conventional clinical or laboratory studies. The
consensus view supports the concept of a geneti-
cally-susceptible host in KD6,83 and there is growing
realisation that immunogenetic studies may reveal
much about the disease and improve diagnosis,
treatment and prognosis. Immunogenetic data sug-
gest a number of plausible associations. Many stu-
dies focus on putative downstream outcome
determinants and suggest a role for mediators of
innate inflammation,84 endothelial activation85 and
cardiovascular homeostasis.86 Studies of suscept-
ibility determinants are more limited. There are
associations with class I regions of the Human Leu-
cocyte Antigen (HLA) in Japanese,87 with different
alleles associated in Caucasians.88 However, these
HLA studies are largely historical and further work
using modern HLA typing techniques are warranted.
Unfortunately, genetic studies of KD have often
been undermined bymethodological problems89 that
dog many such studies of human complex disease.
Thus some of the reported associations are likely to
be false positive results. In particular, the studies
often lack statistical power, employ multiple uncor-
rected statistical comparisons andmany do not repli-
cate findings in an independent population.87,88,90—92
Case-control methodology in a multi-ethnic disease
may yield spurious disease associations (type I errors)due to population admixture,93 unless this is actively
identified.94 Inadequate marker density in candidate
loci,where the functional variants are unknown,may
increase type II errors.89Conclusions and future directions
Kawasaki disease is a fascinating and important
paediatric illness, which presents a significant diag-
nostic challenge. It is the most common cause of
heart disease acquired in childhood and an impor-
tant paradigm for understanding the determinants
of adult cardiovascular pathology. The epidemiology
is well characterised and clearly supports the view
that the disease results from an inappropriate
immunological response to one or more infectious
triggers in genetically-susceptible individuals. The
search for the microbial etiology has been disap-
pointing and unsuccessful and all that remains of
over three decades of such studies is a ‘long list of
discarded pathogens’.3 Understanding the genetic
determinants of susceptibility to KD and those
involved in mediating coronary artery damage
may be a more profitable approach. The methodo-
logical issues that have undermined genetic ana-
lyses can be largely overcome by international
collaborative studies that employ standardised phe-
notypic definitions and large sample sizes derived
from different ethnic groups. The use of family-
based genetic association analyses95 circumvents
the problems of population stratification and the
use of trans-racial mapping (i.e. investigating
genetic determinants in different ethnic groups)96
may prove important to defining the critical genetic
determinants, particularly in regions of high linkage
disequilibrium. Newer molecular techniques, parti-
cularly gene expression profiling and proteomics
may identify novel molecular ‘fingerprints’ that
differentiate KD from other febrile and inflamma-
tory illnesses.3 The mystery of KD may ultimately be
solved by looking within the host.
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